Clinical Utility of Lipoprotein(a) for Screening Does Not Determine Clinical Utility of Lipoprotein(a) for the Patient-Reply

Mark Trinder^{1

2}, Pradeep Natarajan^{2

3

4

5}

Affiliations

¹ Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada.
² Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard, Cambridge, Massachusetts.
³ Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston.
⁴ Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
⁵ Cardiovascular Research Center, Massachusetts General Hospital, Boston.

Comment

Mark Trinder et al. JAMA Cardiol. 2021.

. 2021 Sep 1;6(9):1097.

doi: 10.1001/jamacardio.2021.1589.

Mark Trinder^{1

2}, Pradeep Natarajan^{2

3

4

5}

¹ Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada.
² Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard, Cambridge, Massachusetts.
³ Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston.
⁴ Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
⁵ Cardiovascular Research Center, Massachusetts General Hospital, Boston.

No abstract available

Comment on

Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease.
Trinder M, Uddin MM, Finneran P, Aragam KG, Natarajan P. Trinder M, et al. JAMA Cardiol. 2021 Mar 1;6(3):287-295. doi: 10.1001/jamacardio.2020.5398. JAMA Cardiol. 2021. PMID: 33021622 Free PMC article.
Clinical Utility of Lipoprotein(a) for Screening Does Not Determine Clinical Utility of Lipoprotein(a) for the Patient.
Schrock CG. Schrock CG. JAMA Cardiol. 2021 Sep 1;6(9):1096-1097. doi: 10.1001/jamacardio.2021.1592. JAMA Cardiol. 2021. PMID: 34106204 No abstract available.